The Resistance of Cervical Cancer to Chemotherapy and its Reversal by S. Muthusami - ISBN: 9780443223525
Hardcover
Overcoming cervical cancer’s tough resistance to chemotherapy.

The Resistance of Cervical Cancer to Chemotherapy and its Reversal

$377.18

  • Hardcover

    364 pages

  • Release Date

    27 March 2026

Check Delivery Options

Summary

The Resistance of Cervical Cancer to Chemotherapy and its Reversal

This book delves into the complex issue of cervical cancer’s resistance to chemotherapy. It explores the underlying mechanisms that allow cancer cells to evade the effects of these treatments and discusses promising strategies for overcoming this resistance.

The text examines:

  • Mechanisms of Resistance: Understanding how cervical cancer cells develop resistance to various chemoth…

Book Details

ISBN-13:9780443223525
ISBN-10:0443223521
Author:S. Muthusami
Publisher:Elsevier Science Publishing Co Inc
Imprint:Academic Press Inc
Format:Hardcover
Number of Pages:364
Release Date:27 March 2026
Weight:450g
Dimensions:235mm x 191mm
Series:Breaking Tolerance to Anti-Cancer Cell-Mediated Immunotherapy
About The Author

S. Muthusami

Dr. Sridhar Muthusami completed his Ph.D in endocrinology in 2011 from the University of Madras, India. His doctoral study delineated the molecular mechanism underlying the anabolic actions of Cissus quadrangularis, an indigenous herb believed to exert anabolic effects on bone cells through IGFR. After his Ph.D, he pursued postdoctoral work in the department of Radiation Oncology, Chungbuk National University, South Korea, from 2011 to 2014. There, he worked on the role of Epidermal growth factor/receptor (EGF/EGFR) signaling and its regulation of oncoprotein Fused Toes Homolog (FTS) in cervical cancer cells. He also investigated the role of T0070907/EGCG/cordycepin on cervical cancer cells. Since 2015, he has been with the department of biochemistry, Karpagam Academy of Higher Education (Deemed to be University), serving as Associate Professor and Head at Cancer Research Centre, working on the development of EGFR TKIs for the treatment/management of cervical cancer/pancreatic cancer.

Returns

This item is eligible for free returns within 30 days of delivery. See our returns policy for further details.